CoreWeave's AI Surge Reaches $55B in Orders, Yet $12B in Capital Spending and Debt Raise Concerns Over Profitability
- CoreWeave reported $1.36B Q3 revenue (134% YoY) and $55.6B backlog, driven by AI cloud demand. - Stock fell 3.68% despite $12B 2025 CapEx, $110M net loss, and CEO selling $5.7M shares. - Partnership with CrowdStrike aims to secure AI infrastructure, but investors question profitability. - 2026 CapEx forecast at $28B raises concerns about converting $55.6B backlog into cash flow.
CoreWeave Inc. (NASDAQ: CRWV) posted impressive results for the third quarter of 2025, achieving $1.36 billion in revenue—a 134% jump from the previous year—and nearly doubling its revenue backlog to $55.6 billion, fueled by escalating demand for AI-focused cloud services.
The quarterly report highlighted CoreWeave’s central position in the AI computing surge, with major clients like OpenAI and Meta Platforms utilizing its GPU-centric infrastructure
Nonetheless, enthusiasm was dampened by financial challenges.
Investor confidence was further shaken when Intrator sold $5.7 million in shares at $113.97 each, raising questions about management’s outlook
The company’s 2026 outlook added to investor skepticism. With capital expenditures expected to top $28 billion—twice the 2025 estimate—stakeholders are closely watching how quickly CoreWeave can turn its $55.6 billion backlog into actual revenue
Even with these short-term challenges, CoreWeave remains a major force in the AI technology race. Its strategic partnerships—including the CrowdStrike deal and a 40,000-GPU rollout with Nvidia-backed Poolside—position it to capitalize on the agentic AI era
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Grayscale's Public Listing: Advancing Crypto Adoption as Regulations Vary Worldwide
- Grayscale files U.S. IPO via S-1, joining crypto firms like Circle and Bullish in public markets. - IPO details remain undetermined, contingent on SEC review and market conditions. - Japan's TSE tightens crypto listing rules amid volatile "crypto hoarding" stock collapses. - U.S. regulators advance crypto rulemaking post-shutdown, potentially accelerating Grayscale's approval. - Grayscale's IPO highlights crypto's institutional push amid global regulatory divergence.

BNY's Stablecoin Fund Connects Conventional Finance with Around-the-Clock Digital Markets
- BNY Mellon launches BSRXX, a regulated fund enabling stablecoin issuers to hold GENIUS Act-compliant reserves without direct stablecoin investments. - The fund supports 24/7 digital markets by providing ultra-safe, short-term liquidity under federal requirements for stablecoin backing. - Anchorage Digital's participation highlights growing institutional adoption, with stablecoin reserves projected to reach $1.5 trillion by 2030. - BNY's $57.8T custody expertise positions it as a key infrastructure provid
Durov's Legal Victory Highlights the Ongoing Struggle Between Privacy and Government Oversight
- French authorities lifted a travel ban on Telegram CEO Pavel Durov after he complied with judicial supervision for a year. - Durov faces charges of complicity in alleged Telegram misuse for crimes, with potential 10-year prison and $550k fine if convicted. - He criticized French legal procedures and Macron's policies, highlighting tensions over digital privacy and blockchain integration. - The case underscores regulatory challenges for encrypted platforms, balancing user rights with accountability in a "

Avient's Improved EBITDA and Efficiency Boost Propel Shares Up by 8%
- Avient's stock rose 8% after Q3 results showed $0.70 adjusted EPS and 16.5% EBITDA margin, driven by productivity gains despite weaker sales. - Organic sales fell across key divisions (-4% in Color/Inks, -1% in SEM), with mixed regional performance and ongoing supply chain challenges. - 2026 guidance ($540M-$550M EBITDA) reflects cautious optimism, while analysts diverged on price targets amid macroeconomic risks and strategic shifts in packaging markets . - Management emphasized defense/healthcare growt
